A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Dapsone Tablets

Sulfone class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2024-09-01
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema7 entries indexed · 4 visible
What is Dapsone Tablets used for?

Dapsone Tablets is a Sulfone medication tracked in Medicare Part D.

Is there a generic for Dapsone Tablets?

No. Dapsone Tablets is brand-only with no generic equivalents currently in market.

How much does my plan pay for Dapsone Tablets?

NADAC pricing data not currently available for this drug.

Is Dapsone Tablets on the FDA shortage list?

No. Dapsone Tablets is not currently on the FDA Drug Shortage Database.

3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Sulfone3 alternatives in D1
01
Dapsone
Brand: ACZONE
$0.512Lowest NADAC
16Generic mfrs
$11.5MCY24 Part D spend
Compare →
02
Dapsone Gel,
Brand: Dapsone
$0.767Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Daspone
Brand: Dapsone
$0.790Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.